Mesenchymal stem cell therapy for liver fibrosis

Area of Science:

• Regenerative Medicine
• Hepatology
• Stem Cell Therapy

Background:

• Liver transplantation is the primary treatment for end-stage liver fibrosis but faces limitations like organ scarcity and high costs.
• Mesenchymal stem cells (MSCs) are emerging as a potential alternative therapy for hepatic diseases.

Purpose of the Study:

• To summarize the properties of MSCs for regenerative medicine in liver fibrosis.
• To review therapeutic mechanisms and clinical applications of MSCs in liver fibrosis.
• To highlight potential risks associated with MSC therapy.

Main Methods:

• Review of existing literature on mesenchymal stem cell properties and therapeutic applications.
• Analysis of MSC mechanisms including differentiation, immune modulation, and trophic factor secretion.
• Evaluation of potential risks such as fibrogenic potential and tumor promotion.

Main Results:

• MSCs possess immune-modulatory properties and secrete trophic factors beneficial for liver regeneration.
• MSC therapy can suppress inflammation, reduce hepatocyte apoptosis, enhance regeneration, and improve liver function.
• MSCs also exhibit fibrogenic potential and can promote tumor cell growth and oncogenicity.

Conclusions:

• Mesenchymal stem cells offer a promising therapeutic avenue for liver fibrosis due to their regenerative and immunomodulatory capabilities.
• Careful consideration of MSCs' risks, including fibrogenic potential and oncogenicity, is crucial for safe clinical translation.